<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02468128</url>
  </required_header>
  <id_info>
    <org_study_id>LT1001-301</org_study_id>
    <secondary_id>SDE-2-001</secondary_id>
    <nct_id>NCT02468128</nct_id>
  </id_info>
  <brief_title>A Study of Intramuscular Sebacoyl Dinalbuphine Ester for Post-Hemorrhoidectomy Pain Management</brief_title>
  <official_title>A Randomized, Double Blind, Placebo-Controlled, Single Dose Study to Assess The Safety and Efficacy of Intramuscular Sebacoyl Dinalbuphine Ester (SDE) for Post-Hemorrhoidectomy Pain Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lumosa Therapeutics Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lumosa Therapeutics Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double blind, placebo-controlled, single dose study to assess the
      safety, efficacy and pharmacokinetics of intramuscular sebacoyl dinalbuphine ester (SDE) for
      post-hemorrhoidectomy pain management.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain assessment calculated as the area under the curve of VAS pain intensity scores through 48 hours after surgery</measure>
    <time_frame>1±0.1, 2±0.1, 3±0.1, 4±0.25, 8±0.5, 12±0.5, 16±0.5, 20±0.5, 24±1, 28±1, 32±2, 36±2, 40±2, 44±2, 48±2 h after the surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Consumption of ketorolac via intravenous Patient- Controlled Analgesia (IV PCA)</measure>
    <time_frame>Day 1-2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain assessment measured with VAS during Day 3-7 in the morning and evening, as well as during special events such as bowel movements.</measure>
    <time_frame>Day 3-7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from the end of operation to the first PCA Ketorolac dose</measure>
    <time_frame>From the end of operation until the first PCA ketorolac dose used, assessed up to 48 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory (BPI)</measure>
    <time_frame>Day 1, 2 and Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consumption of oral Ketorolac (Day 3-7)</measure>
    <time_frame>Day 3-7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction-Subject will be asked to classify themselves as either: 'highly satisfied', 'satisfied', 'uncertain', 'dissatisfied' or 'very dissatisfied'</measure>
    <time_frame>Day 7</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">221</enrollment>
  <condition>Analgesia Disorder</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>SDE 150mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose, intramuscular, Sebacoyl Dinalbuphine Ester injection 150 mg (2 ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose, intramuscular , Sebacoyl Dinalbuphine Ester placebo injection (2mL)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sebacoyl Dinalbuphine Ester</intervention_name>
    <description>Intramuscular injection 2mL/vial (75mg/mL)</description>
    <arm_group_label>SDE 150mg</arm_group_label>
    <other_name>SDE</other_name>
    <other_name>LT1001</other_name>
    <other_name>Nalbuphine Sebacate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sebacoyl Dinalbuphine Ester injection placebo, 2mL/vial</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female &gt;= 20 years of age at Screening

          -  Scheduled to electively undergo 2 or 3-column excisional hemorrhoidectomy

          -  American Society of Anesthesiology Physical Class 1 - 3

          -  Adequate clinical lab values (values of potential clinical concern are detailed in
             Appendix) or, if abnormal, deemed not clinically significant per the Investigator.

          -  Ability and willingness to provide informed consent, adhere to the study visit
             schedule and complete all study assessments and language specific questionnaires

        Exclusion Criteria:

          -  Body weight less than 40 kg.

          -  Concurrent fissurectomy.

          -  Subject is pregnant or breastfeeding. Women of childbearing potential must have a
             negative urine pregnancy test at Baseline.

          -  Women of childbearing potential disagree to use an acceptable method of contraception
             (e.g., hormonal contraceptives, IUD, barrier device or abstinence) throughout the
             study.

          -  History of hypersensitivity or allergy to amide-type local anesthetics, opioid, or any
             ingredient of the medications administered in this study.

          -  Subject has a resting respiratory rate less than 8 per minute and blood oxygen
             saturation less than 90 mmHg.

          -  Use of any NSAIDs, selective COX-2 inhibitors, opioid, acetaminophen, selective
             serotonin reuptake inhibitors (SSRI), tricyclic antidepressants (TCA), gabapentin, or
             pregabalin within three days of surgery.

          -  Chronic use of opioid medications for more than 14 days in the last 3 months, or
             non-opioid pain medications more than 5 times per week before screening visit.

          -  Use of any long-acting opioid medication within 3 days of surgery or any opioid
             medication within 24 hours of surgery.

          -  Current painful physical condition or concurrent surgery requires analgesic treatment
             in the postoperative period.

          -  Contraindication to epinephrine or any of the pain-control agents planned for
             postoperative use.

          -  Administration of an investigational drug within the longer of 30 days or 5
             elimination half-lives of such investigational drug prior to study drug
             administration.

          -  Any psychiatric disorder, psychological, medical, or laboratory condition that may
             interfere with study assessments or compliance.

          -  Significant medical conditions or laboratory results that may indicate an increased
             vulnerability to study drugs and procedures, and thus expose the subject to an
             unreasonable risk as a result of participating in this clinical trial.

          -  Any clinically significant event or condition may be uncovered during surgery.

          -  History of abuse illicit drugs, prescription medicines or alcohol within the past 2
             years.

          -  Known history of anti-HIV antibody positive

          -  Failure to pass drug and alcohol screen.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeng-Yi Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital-Linkuo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital at Chiayi</name>
      <address>
        <city>Putzu City</city>
        <state>Chiayi Hsien</state>
        <zip>61363</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital at Linkuo</name>
      <address>
        <city>Linkuo</city>
        <state>New Taipei City</state>
        <zip>244</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital at Kaohsiung</name>
      <address>
        <city>Kaohsiung City</city>
        <zip>88301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital at Keelung</name>
      <address>
        <city>Keelung</city>
        <zip>20401</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cheng Ching General Hospital</name>
      <address>
        <city>Taichung city</city>
        <zip>40764</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei city</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2015</study_first_submitted>
  <study_first_submitted_qc>June 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2015</study_first_posted>
  <last_update_submitted>July 1, 2015</last_update_submitted>
  <last_update_submitted_qc>July 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Analgesic</keyword>
  <keyword>Opioids</keyword>
  <keyword>Pain relief after surgery</keyword>
  <keyword>Dinalbuphine</keyword>
  <keyword>Sebacoyl Dinalbuphine Ester</keyword>
  <keyword>SDE</keyword>
  <keyword>SDN</keyword>
  <keyword>LT1001</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nalbuphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

